This Web Site is committed to the memory of Janis Morrow.
Internet Conferences
November 2009
AASLD 2009 Conference News
The Liver Meeting is the premier event in the science and practice of hepatology. Designed for physicians, surgeons, scientists, educators, nurses, physician assistants, and all other hepatology health professionals.
Nov 10
|
AASLD:
AASLD: New Drug Boosts HCV Clearance
Boceprevir is one of two HCV protease inhibitors in late-stage development, the other being telaprevir
|
||
BOSTON -- Most hepatitis C patients who are
initially unresponsive to standard therapy were able
to achieve sustained virologic responses when the
investigational drug boceprevir was added, a
researcher reported here.
Sustained responses were seen in 55% of patients receiving 44 weeks of boceprevir after showing no virologic response to four weeks of pegylated interferon-alfa-2b (PEGIntron) and ribavirin (Rebetol) in a Phase II trial, said Paul Kwo, MD, of Indiana University in Indianapolis. Kwo, speaking here at the American Association for the Study of Liver Disease meeting, was reporting on two secondary analyses of data from the SPRINT-1 trial of boceprevir, an inhibitor of the hepatitis C virus (HCV) NS3 protease enzyme. He had presented the main findings of the 520-patient study earlier this year at the European Association for the Study of the Liver meeting in Copenhagen. (See Sustained Response Seen with New Hepatitis C Drug)
Action Points
Boceprevir is one of two HCV protease inhibitors in late-stage development, the other being telaprevir. (See DDW: Telaprevir Improves HCV Clearance in Resistant Patients) Phase III trials of both drugs are now under way. In the SPRINT-1 trial, treatment-naive patients were randomized to five treatment arms, including one in which patients only received pegylated interferon and ribavirin, two involving immediate treatment with all three agents, and two in which boceprevir started after an initial, four-week lead-in with interferon and ribavirin. All patients had HCV genotype 1a or 1b, mostly the former. The secondary analyses reported here focused only this last treatment strategy, with patients receiving either 24 or 44 weeks of triple therapy following the four-week, two-drug lead-in. Boceprevir was dosed at 800 mg three times a day. In patients with no response to the lead-in -- defined as a reduction in HCV RNA loads of less than ten-fold -- 25% of those receiving boceprevir for 24 weeks still showed viral clearance after an additional 24 weeks of follow-up. With 55% of initial null responders receiving the drug for 44 weeks showing long-lasting viral clearance, the longer therapy appeared to be more effective, Kwo said. He also noted that boceprevir for both durations boosted response rates well above what would normally be expected from standard therapy in patients without strong responses in the first four weeks. He cited results from an earlier large trial in which less than 5% of early nonresponders to standard therapy eventually developed sustained responses. Among patients showing strong responses in the first four weeks of interferon and ribavirin, sustained responses were seen in most. More than 80% of those with initial reductions of three to four orders of magnitude in viral RNA levels had sustained responses, as did nearly 100% of those with reductions of at least four orders of magnitude or whose viral RNA became undetectable in the first four weeks. Duration of boceprevir treatment appeared to make no difference in sustained virologic response rates in these patients. But Kwo cautioned that the findings in these analyses involved relatively small numbers of patients. Only about 50 patients were considered null responders to the lead-in treatment, and similar numbers had relatively strong initial responses. Overall, adding boceprevir after the four-week lead-in led to sustained responses in 56% of patients receiving boceprevir for 24 weeks, and in 75% of those taking the drug for 44 weeks, Kwo said. Both response rates were significantly (P<0.01) higher than the 38% rate seen in patients taking only pegylated interferon and ribavirin for 48 weeks. In a separate analysis, Kwo reported that virologic responses measured later in treatment could identify patients for whom longer or shorter boceprevir treatment would be most appropriate. For example, only the 18% of patients whose viral RNA became undetectable after four to 12 weeks of boceprevir treatment (after the four-week lead-in with standard therapy) appeared to need the full 44 weeks of boceprevir to hold the response, Kwo said. The remaining 82% all achieved viral clearance within four weeks of starting boceprevir. He said he hoped the Phase III trial would confirm that most patients could get by with the shorter regimen. He added that the overall data suggested that HCV protease inhibitors may act primarily to restore sensitivity to interferon, though he emphasized that this theory would have to be confirmed in future studies.
The study was funded by Schering-Plough.
Kwo reported relationships with Schering-Plough, Vertex, Novartis, Gilead, Abbott, Roche, Merck, GlaxoSmithKline, Celgene, Idenex, and Bristol-Myers Squibb. Several co-authors were employees of Schering-Plough. |
||
|
Primary source: Hepatology Source reference: Kwo P, et al "High sustained virologic response (SVR) in genotype 1 (G1) null responders to peg-interferon alfa-2b (P) plus ribavirin (R) when treated with boceprevir (Boc) combination therapy" Hepatology 2009; 50: 331A-332A. Additional source: Hepatology Source reference: Kwo P, et al "Response-guided therapy (RGT) for boceprevir (Boc) combination treatment? – Results from HCV SPRINT-1" Hepatology 2009; 50: 1035A-1036A. |
Nov 15
October 30-November 3, 2009 Boston, Massachusetts
Nov 5
Pharmasset
PSI-7851
|
Nov 2, 2009 |
AASLD Investor Event
|
Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which has completed initial Phase 1 clinical studies, and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.
Pegasys(R) and Copegus(R) are registered trademarks of Roche
Slide Presentation
AASLD 2009 Updates
Pegylated Interferon/Ribavirin Can Treat Both HCV/HBV Dually
Geno 1 HCV Patients Low Viral Load Can Achieve SVR 24wks with Pegylated Interferon and Ribavirin
Nov 18
Patients With More Difficult To Treat Forms Of Hepatitis C Are Half As Likely To Treat The Disease
Nov 11
Nov 10
2 Oral HCV Drug Combination R7227+R7128
Nov 09
Telaprevir PROVE3 Final Results: treatment-experienced patients
Nov 6
Study results of nucleoside polymerase and protease inhibitor (R7227/ITMN-191)combination therapy for HCV promising
Vitamin D Has Benefits in Chronic HCV Infection
AASLD: HCV Now an STD in New York
Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)
Nov 5
IMO-2125 Induces Endogenous Interferons and Other Antiviral Proteins -
Nov 4
AASLD: New Drug Boceprevir Boosts HCV Clearance for Nonresponders -
Canadian programs underscore evidence of PEGETRON's positive outcomes in treating HCV infection
Oral/AVL-181 HCV protease inhibitor/AASLD
Nov 2
Schering hep C drug promising in Phase II study
Drug Telaprevir Effective in Twice Daily Dosage as Well
Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C
Individually Tailored Duration of Hepatitis C Treatment Does Not Improve Virological Response
Nov 1
Liver Transplants
Nov 5
Viral Load Predicts Outcome of Liver Transplant Recipients with Hepatitis C: Presented at AASLD
Noninvasive Breath Test Predicts Survival in Patients with Viral Hepatitis
Nov 4
Extending Treatment After Liver Transplant May Benefit Patients With Hepatitis C Recurrence
Post-transplant Prophylactic Antiviral Treatment Does Not Prevent Recurrent Hepatitis C
For Adult-To-Adult Living Donor Liver Transplantation, Left Side Grafting Is Procedure Of Choice
Nov 1
HCV Advocate’s AASLD Conference coverage
Welcome to the HCV Advocate’s AASLD Conference coverage. In an effort to best serve our readership, we will post all the important and interesting abstracts about HCV from the conference. While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted. The other abstracts posted to the web site are HCV related abstracts posted to www.aasld.org that we have not been able to report on or update.
To locate specific abstracts for each topic below, click on the links.
Please click here to view our fact sheet on reading and understanding an abstract.
Thank You,
Alan Franciscus
Editor-in-Chief
● Clinical Trials: New treatments for hepatitis C that have been studied in humans, and various drugs that are in phase I, II and III development to treat hepatitis C.
● Diagnostic Tools: Various tests to diagnose and manage hepatitis C including various biochemical marker, imaging, liver biopsy for grading/staging liver disease and HCV RNA (viral load) tests.
●
Epidemiology & Transmission Issues:
Studies that look at populations infected with hepatitis C as
well as the transmission risk factors.
● HCV Treatment: The current treatments for hepatitis C, including outcomes, side effects and treatment of various HCV populations.
● Natural History: HCV symptoms, disease progression and management.
|
HIV and Hepatitis.com
Coverage of the
60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) October 30 - November 3, 2009, Boston, MA |
|
The Best of the Liver Meeting® 2009
June
Digestive Disease Week
May 30 - June 4, 2009, Chicago, Illinois
Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
Asian-American Chronic Hepatitis C Patients Respond Well to Pegylated Interferon plus Ribavirin
Asian-Americans Are More Likely to Have Unknown Hepatitis C Virus Transmission Risk Factors
Many People with Chronic Hepatitis B and C Do
Not Receive Appropriate Treatment
Strategies for Managing
Acetaminophen-related Liver Disease and Acute Liver
Failure
6-5-2009
Vitamin B12 Levels May Help Predict Response to
Interferon-based Therapy for
Chronic Hepatitis C
6-5-2009
High HBV DNA Level Is the
Strongest Predictor of Elevated ALT
6-9-2009
Should Entecavir (Baraclude) and Tenofovir
(Viread) Be First-line Treatment for Chronic Hepatitis B?
6-5-2009
April-May
May 30th-June 4
April 22-26 2009
EASL 2009
European Association for the Study of the Liver
Copenhagen, Denmark
The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver (EASL), is taking place in Copenhagen, Denmark, 22 April 2009. The official website is: http://www.easl.eu. Over 7,000 clinicians and scientists are expected to attend EASL 2009. Over the course of the Meeting, 144 oral presentations and 199 posters drawn from over 2179 abstract submissions will be featured.
EASL: EASL Analysis, New Oral HCV Drugs What's Expected - (05/14/09)
EASL: BASELINE CHARACTERISTICS AND WEEK 4 RESPONSE AMONG CHRONIC HEPATITIS C PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 OR 4: INTERIM RESULTS OF THE PROPHESYS TRIAL - (05/13/09)
EASL: Identifying Patients Infected With HCV Genotype 1 Who May Benefit From Extended Peginterferon Alfa-2a/Ribavirin Therapy Beyond 48 Weeks - (05/13/09)
EASL: Ursodeoxychic Acid Improved NASH, Not So Sure About Rosiglitazone - (05/12/09)
EASL: Single and Multiple-Dose Assessments of the Safety and Pharmacokinetics of SCH 900518 and Its Effect on the Pharmacokinetics of Midazolam in Healthy Subjects - (05/12/09)
EASL: Preclinical Characterization of SCH 900518,A Novel Mechanism-Based Inhibitor of HCV NS3 Protease - (05/12/09)
EASL: Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor - (05/11/09)
EASL: Preclinical Profiles of IDX136 and IDX316, Two Novel Macrocyclic HCV Protease Inhibitors - (05/11/09
EASL: IDENTIFICATION AND PROFILE OF POTENT AND SELECTIVE INHIBITORS OF HCV NS5A PROTEIN - (05/11/09)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection...PROVE1 in NEJM 4/2009 - (05/08/09)
EASL: Albuferon vs Pegasys Genotype 2/3 - (05/07/09)
EASL: Albuferon vs Pegasys Genotype 1 - (05/07/09)
EASL: Co Press Release: Biolex presents Locteron US Phase 2a hepatitis C data at EASL - (05/07/09)
EASL: Identification and Characterization of VCH-222, a Novel Potent and Selective Non-Nucleoside HCV Polymerase Inhibitor - (05/07/09)
EASL: Activity & Genotypic and Phenotypic Analysis of HCV NS5B Variants Selected from Patients Treated with VCH-916 - (05/07/09)
EASL: Preclinical Pharmacokinetic and ADME Characterization of VCH-222, a Novel Non-Nucleoside HCV NS5B Polymerase Inhibitor from Vertex/ViroChem - (05/07/09)
EASL: IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor: Results of a First-in-Man Safety and Pharmacokinetic Study - (05/07/09)
EASL: Albuferon vs Pegasys Genotype 1 - (05/06/09)
EASL: Characterization of Resistance Mutations Selected In Vitro by Non-Nucleoside HCV Polymerase Inhibitors ABT-333 and ABT-072 - (05/06/09)
EASL: US Hepatitis C Burden Assessment from a Transmission Model: HCV burden reduced by new HCV drugs - (05/06/09)
EASL: Pharmacokinetics and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Single Ascending Doses in Healthy Adult Volunteers - (05/06/09)
EASL: Safety, Tolerability, and Pharmacokinetics of GS-9450 in Healthy Male and Female Volunteers - (05/05/09)
EASL: Abbott/Enanta - Potent HCV Protease Inhibitors with the Potential for Once-daily Dosing and Broad Genotype Coverage - (05/05/09)
EASL: Preclinical Characterization of ABT-072: A Novel Non-Nucleoside HCV Polymerase Inhibitor - (05/05/09)
EASL:
Preclinical Potency, Pharmacokinetic and ADME Characterization of
ABT-333, A Novel Non-Nucleoside HCV Polymerase Inhibitor -
(05/05/09
EASL: HCV SPRINT-1: Final Results SVR 24 NS3 Protease Inhibitor Boceprevir plus PegIFN alpha-2b/Ribavirin HCV 1 Treatment Naïve Patients - (04/30/09)
EASL: Antiviral Activity and Safety of ITMN-191 (R7227) in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus - (04/29/09)
EASL: Subgroup Analysis Confirms Efficacy, Safety of Sorafenib in Patients With Late-Stage Liver Cancer: Presented at EASL - (04/29/09)
EASL: A FIRST CLINICAL TRIAL OF THERAPEUTIC VACCINATION USING NAKED DNA DELIVERED BY IN VIVO ELECTROPORATION SHOWS ANTIVIRAL EFFECTS IN PATIENTS WITH CHRONIC HEPATITIS C - (04/29/09)
EASL: Safety, Tolerability, and Pharmacokinetics after Single and Multiple Doses of MK-3281 in Healthy Subjects - (04/28/09)
EASL:
Metabolic Syndrome Hikes Mortality in Hepatitis C - (04/28/09)
EASL: Ground-Breaking Combination of 2 All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen (ITMN-191 protease + R7128 NRTI) - (04/28/09)
EASL:
FDA Regulations for HCV Drug Development - are they too Strict?
- (04/28/09)
EASL: Can Peginterferon and Ribavirin Be Eliminated from Therapy - (04/28/09)
EASL: Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C - (04/28/09)
EASL: OPERA-1 trial (Study TMC435-C201): interim analysis of safety and antiviral activity of TMC435 in treatment-naÏve genotype-1 HCV patients - (04/28/09)
EASL: EASL Day 3 Saturday - (04/28/09)
EASL:
HCV Protease ITMN-191 + Peg/RBV for 14 Days - safety, antiviral
activity - (04/28/09)
EASL: SCH-900518 New Schering Protease Inhibitor Monotherapy & with Peg/RBV 7-14 days - (04/28/09)
EASL:
Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128,
Most Advanced Nucleoside Polymerase Inhibitor in Development for
Chronic Hepatitis C - (04/28/09)
EASL: Peg-Interferon lambda + Ribavirin 4 Weeks - (04/28/09)
EASL:
Telaprevir Effective for Genotype 2 But Not For Genotype 3 -
(04/27/09)
EASL: Maintenance Therapy: we don't know if it provides benefit - (04/27/09)
EASL: HIV positive and HIV negative patients have similar survival rates following liver transplant - (04/27/09)
EASL: Anadys shares plunge on hepatitis C drug ANA598 safety concerns - (04/27/09)
EASL: Schering's protease boceprevir phase 2; Schering symposium - (04/27/09)
EASL: Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days' oral treatment in patients with chronic hepatitis C - (04/27/09)
EASL: ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients - (04/24/09)
EASL: Tibotec HCV Protease TMC435 I Treatment-Naives Genotype 1, Monotherapy & Combination with Peg/RBV - (04/24/09)
EASL: New HCV Drugs II: Schering's protease boceprevir phase 2; Abbott/Enanta HCV Protease Inhibitors; Progenics PRO-206 HCV Entry Inhibitor - (04/24/09)
EASL: Taribavirin vs Ribavirin - (04/24/09)
EASL: New HCV Drugs Today at EASL 1st Day - (04/24/09)
EASL: EASL New HCV Drugs - (04/23/09)
EASL:
EPIC Study Shows Maintenance Therapy Provides Benefits -
Low-Dose Naltrexone Eases Pain and Fatigue of Fibromyalgia - (04/22/09)
Metabolic Syndrome Hikes Mortality in Hepatitis C
By John Gever, Senior Editor, MedPage Today
March 2009
13th International Symposium on Viral Hepatitis and Liver Disease
March 20-24, 2009
Washington, DC
Pegylated Interferon Monotherapy for Treatment of Chronic Hepatitis B
ImQuest Identifies First Non-nucleoside Inhibitors of Hepatitis B Virus
Studies Shed More Light on Acute Hepatitis C among HIV Positive Men in the U.S. and Europe
Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
TMC435 HCV Protease Inhibitor Safety/antiviral activity OPERA Study doses 25 & 75 mg once daily -
Screening for Acute Hepatitis C Virus Infection (AHCV) among At-Risk Patients in an HIV Clinic -
Treatment for Hepatitis B: When to Start, What to Use, and When to Stop
HCV Reinfection and Superinfection Are Common among Injection Drug Users
| Safety and antiviral activity of TMC435 (TMC435350) in treatment-naïve genotype 1 HCV-infected patients Study TMC435-C201 |
|
|
Tenofovir (Viread) during Pregnancy: Findings from the Antiretroviral Pregnancy Registry
Abstracts
The abstracts for the 13th International Symposium on Viral Hepatitis and Liver Disease are now available.
-
Download – Oral Abstracts for Saturday, March 21
-
Download – Oral Abstracts for Sunday, March 22
-
Download – Oral Abstracts for Monday, March 23
-
Download – Oral Abstracts for Tuesday, March 24
-
Download – Poster Presentation Abstracts
-
Download – Invited Speaker Abstracts
Also See:
HIV and Hepatitis.com Coverage of the
13th International Symposium on Viral
Hepatitis and Liver Disease (ISVHLD 2009)
March 20 - 24, 2009, Washington, DC
Sept 2008
Join Or Visit Our Message Boards For Coverage
AASLD/EASL/DDW
CONFERENCE NEWS
Coverage Can Be Found At The Following Sites:
From: HIV and Hepatitis.com Coverage
May-April 2008
HIV and Hepatitis.com
Coverage of
DIGESTIVE DISEASE WEEK (DDW 2008)
May 17 - 22, 2008, San Diego, California
Janis and Friends Forum: Read and Comment on EASL& DDW Coverage.
HIV and Hepatitis.com
Coverage of the
43rd
EASL Conference
(EASL 2008)
April 23 - 27, 2008,
Milan Italy
Nov 2007
HIV and Hepatitis.com Coverage of the
58th Annual Meeting of the American Association
for the Study of Liver Diseases (AASLD 2007)
November 2-6, 2007, Boston, MA
Welcome to the HCV Advocate’s AASLD Conference coverage. In an effort to best serve our readership, we will post all the important and interesting abstracts about HCV from the conference. While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted.
APRIL 2007
42nd EASL
April 11 - 15, 2007
Barcelona, Spain
THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
November 2006
Coverage of 57th Annual Meeting of the American Association for the Study of Liver Disease
Oct 27-31,2006, Boston MA
NATAP
HCV Advocate
May 2006
May 20 - 25, 2006, Los Angeles, California
Coverage of the
41st Annual Meeting of the
European Association for
the Studyof the Liver
(41st EASL)
April 26 - 30, 2006,
Vienna, Austria
|
From Janis and Friends:
Nov 11 - 15, 2005 San Francisco, CA
Join our Forum in order to discuss the AASLD
Or
click below and enter as our guest to read the conference news
HIVandHepatitis.com Coverage of Highlights from the
56th Annual Meeting of the American Association for the Study of Liver Diseases Nov 11 - 15, 2005 San Francisco, CA
HCV Advocate’s AASLD Conference coverage
From Janis and Friends:
May 14 - 19, 2005
Digestive Disease Week
2005 (DDW 2005)
From HIV and Hepatitis :
From HCV Advocate :
From Janis and Friends:
April 13-17 2005
40th Annual meeting of the European
Association for the Study of the Liver
(40th EASL)
From HIV and Hepatitis :
Highlights from the
40th Annual meeting of the European Association for the Study of the Liver (40th EASL) April 13 - 17, 2005, Paris, France
Highlights from the
1st European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-infected Patients March 1-2, 2005, Paris, France AASLD 2004 Research Conferences Oct 29- Nov 1 2004 Research Conferences Our message boards have the latest reports coming out of the AASLD . Here you can also comment on the research. HIVandHepatitis.com and HCVAdvocate.org are the best sites for the AASLD 2004 Research Conferences . Clicking below will take you away from our site, click on your back button to return to Janis and Friends From HIVandHepatitis.com :
55th Annual Meeting of the American
Society for the Study of Liver Diseases (55th AASLD) From HCV Advocate :
Digestive Disease Week 2004 (DDW 2004)
May 15 - 20, 2004, New Orleans, LA
Selected Highlights from the
http://www.hivandhepatitis.com/2004icr/39easl/main.html39th Annual Meeting of the European Association for the Study of the Liver (39th EASL) April 14 - 18, 2004, Berlin Germany Compiled by Ronald Baker, PhD
|
||
|
|
||
|
HCV World News & Research |
||
|
Conference AASLD Oct 2003 |
||
|
Conference DDW May 2003 |
||
|
Conference European Assoc Mar 2003 |
||
|
|
||
| AASLD Conference 2001 |

